Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

599.32 -3.50 (-0.58%)
Streaming Delayed Price Updated: 10:20 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today? ↗
Madrigal Pharmaceuticals (MDGL) stock is rocketing higher on Monday after sharing positive results from its NASH treatment. 
Via InvestorPlace
News headline image
Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park ↗
The company hit both of its goals in a Phase 3 study of a pill for the liver disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Madrigal Shares Skyrocket After Successful NASH Study ↗
 
Via Benzinga
News headline image
Tesla, Amazon, Madrigal Pharma, Pfizer, Synaptogenix: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
Major Wall Street indices had closed in the red on Friday in the wake of a continued sell-off following the hawkish stance asserted by the Federal Reserve. Friday witnessed volatile trading as a large... 
Via Benzinga
News headline image
2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter ↗
These two healthcare stocks could deliver market-crushing gains by year's end. 
Via The Motley Fool
News headline image
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis ↗
 
Via Benzinga
News headline image
Recap: Madrigal Pharmaceuticals Q1 Earnings ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health ↗
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has  
Via Benzinga
News headline image
Madrigal Pharmaceuticals: Q3 Earnings Insights ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022 ↗
 
Via Benzinga
News headline image
Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma. 
Via Talk Markets
News headline image
Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch ↗
 
Via Benzinga
News headline image
Tough Slogging Ahead for Investors, Diversification is Important ↗
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
News headline image
Earnings Scheduled For May 9, 2022 ↗
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
News headline image
Madrigal Pharmaceuticals: A "Best in Class" Biotech Buy ↗
One of the few broadly positive binary events in biotechnology of late, Madrigal’s best-in-class NASH compound is well on its way with de-risked, late-stage clinical results. 
Via Talk Markets
News headline image
Bear Market Bets In Biotech ↗
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 333.5% to $2.79 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 19.4... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1... 
Via Benzinga
News headline image
Top Picks For 2022: Madrigal Pharmaceuticals ↗
Madrigal Pharmaceuticals is poised to deliver positive Phase III data in 2022 for resmetirom, its best-in-class NASH (nonalcoholic steatohepatitis) compound. 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.